MEMORANDUM

TO: North Carolina Immunization Program (NCIP) Providers

FROM: Brandon Rector, MSW
Vaccine Distribution Manager

SUBJECT: Announcement of Change in Supply of Boostrix® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis, Tdap, Vaccine) Pre-filled Syringes

The purpose of this memo is to notify immunization providers on behalf of vaccine manufacturer GlaxoSmithKline (GSK) that there will be an upcoming interruption in the supply of Boostrix® in the pre-filled syringe presentation. The interruption is temporary and is expected to begin in early 2013. This supply interruption will only impact the pre-filled syringe presentation of Boostrix® and not the vial presentation. GSK expects to be able to supply enough vials to the market to cover all of the pre-filled syringe demand.

Although we are unable to estimate when it may occur, this interruption may affect vaccines distributed through the NCIP. Should NCIP supplies of Boostrix® syringes be depleted, providers ordering that formulation will have their orders filled with single-dose vials without prior notification by the NCIP. Providers requiring a syringe formulation may choose to order Adacel®, however, we are unable to advise providers as to when ordering practices will change. When supplies have normalized, providers will again receive their preferred formulation of Tdap vaccine.

If you have questions or concerns about your private supply of Boostrix®, contact GlaxoSmithKline. You may reach GSK at 1-866-GSK-VACC (1-866-475-8222) or contact your GlaxoSmithKline Vaccines representative today.

If you have questions about your state-supplied Boostrix®, you may contact our Help Desk at 1-877-873-6247.

Cc: SMT Field Staff Taryn Edwards Central Office Staff Terry Pennington Vaccine Manufacturers Joy Reed Steve Shore Peter Graber Maclyn Powell